TISIDB

Summary
Symbol	AATF
Name	apoptosis antagonizing transcription factor
Aliases	DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location	17q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus, nucleolus
Domain	PF13339 Apoptosis antagonizing transcription factor PF08164 Apoptosis-antagonizing transcription factor
Function	May function as a general inhibitor of the histone deacetylase HDAC1. Binding to the pocket region of RB1 may displace HDAC1 from RB1/E2F complexes, leading to activation of E2F target genes and cell cycle progression. Conversely, displacement of HDAC1 from SP1 bound to the CDKN1A promoter leads to increased expression of this CDK inhibitor and blocks cell cycle progression. Also antagonizes PAWR mediated induction of aberrant amyloid peptide production in Alzheimer disease (presenile and senile dementia), although the molecular basis for this phenomenon has not been described to date.

> Gene Ontology [ TOP ]
Biological Process	GO:0006801 superoxide metabolic process GO:0007346 regulation of mitotic cell cycle GO:0009100 glycoprotein metabolic process GO:0009101 glycoprotein biosynthetic process GO:0010559 regulation of glycoprotein biosynthetic process GO:0010561 negative regulation of glycoprotein biosynthetic process GO:0022613 ribonucleoprotein complex biogenesis GO:0032928 regulation of superoxide anion generation GO:0032929 negative regulation of superoxide anion generation GO:0040016 embryonic cleavage GO:0042254 ribosome biogenesis GO:0042554 superoxide anion generation GO:0042982 amyloid precursor protein metabolic process GO:0042983 amyloid precursor protein biosynthetic process GO:0042984 regulation of amyloid precursor protein biosynthetic process GO:0042985 negative regulation of amyloid precursor protein biosynthetic process GO:0072593 reactive oxygen species metabolic process GO:0090322 regulation of superoxide metabolic process GO:1903018 regulation of glycoprotein metabolic process GO:1903019 negative regulation of glycoprotein metabolic process GO:2000377 regulation of reactive oxygen species metabolic process GO:2000378 negative regulation of reactive oxygen species metabolic process
Molecular Function	GO:0030275 LRR domain binding GO:0043522 leucine zipper domain binding GO:0048156 tau protein binding
Cellular Component	GO:0005813 centrosome GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0030055 cell-substrate junction

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-204998: Cell death signalling via NRAGE, NRIF and NADE R-HSA-193648: NRAGE signals death through JNK R-HSA-162582: Signal Transduction R-HSA-166520: Signalling by NGF R-HSA-193704: p75 NTR receptor-mediated signalling

Summary
Symbol	AATF
Name	apoptosis antagonizing transcription factor
Aliases	DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location	17q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between AATF and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	AATF
Name	apoptosis antagonizing transcription factor
Aliases	DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location	17q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of AATF in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.59	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	AATF
Name	apoptosis antagonizing transcription factor
Aliases	DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location	17q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of AATF in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.166	0.516
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.397	0.863
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.006	0.997
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.121	0.665
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.169	0.936
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.061	0.982
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.124	0.726
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.079	0.961
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.153	0.933
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0	1
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0	1
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.125	0.0128

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of AATF in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	2.7	1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	AATF
Name	apoptosis antagonizing transcription factor
Aliases	DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location	17q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AATF. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	AATF
Name	apoptosis antagonizing transcription factor
Aliases	DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location	17q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AATF. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AATF. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	AATF
Name	apoptosis antagonizing transcription factor
Aliases	DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location	17q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AATF. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	AATF
Name	apoptosis antagonizing transcription factor
Aliases	DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location	17q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of AATF expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	AATF
Name	apoptosis antagonizing transcription factor
Aliases	DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location	17q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between AATF and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	AATF
Name	apoptosis antagonizing transcription factor
Aliases	DED; CHE-1; BFR2; apoptosis-antagonizing transcription factor; rb-binding protein Che-1; Protein AATF
Chromosomal Location	17q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting AATF collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse AATF